

## CEO Meeting

### Pharmacy Update

- The AHCCCS FFS Program will be implementing a new PBM for pharmacy benefit management services on October 1, 2015. The new PBM is OptumRx.
- The contract with Phoenix Children's Hospital to provide hemophilia factor product has been extended for 18 months through January 31, 2017.
- Opioids  
AHCCCS distributed and solicited comments for the draft policy, Monitoring Controlled and Non-Controlled Medication Misuse, at the Pharmacy & Therapeutics Committee and Medical Directors Meetings. AHCCCS is in the process of updating the proposed policy, sending it for legal review and then it will be presented at the AHCCCS Policy Committee for final review.

The policy had intended to utilize the Morphine Equivalence Dosing, which is cross-referencing various controlled substances to an equivalent dose of morphine. This will be a future expectation.

The AHCCCS Quality Department implemented the Pharmacy Performance Improvement Plan, which emphasizes the registration and utilization of the State Board of Pharmacy's Controlled Substance Prescription Monitoring Program (CSPMP) by Contractors' Prescribing Clinicians.

The State Board of Pharmacy will be providing CSPMP data to AHCCCS that will be distributed to Contractors for evaluation.

The AHCCCS Pharmacy & Therapeutic Committee is discussed reducing the quantity limit for short-acting narcotics from 180 to 120. We are evaluating the prior authorization burden if this reduction is finalized.

- Supplemental Rebates  
Magellan Medicaid Administration, formerly known as Provider Synergies, will be facilitating the supplemental rebate process.

A link from our website to the Magellan/Provider Synergies website will be available on the AHCCCS website under the Pharmacy Information Section. The link is [www.providersynergies.com](http://www.providersynergies.com)

The following documents that will be available for review on the site include:

- A Manufacturer Letter on AHCCCS letterhead that introduces Magellan acting on our behalf to solicit and obtain supplemental rebates.
- The AHCCCS Minimum Required Prescription Drug List
- Therapeutic Classes and Products scheduled to be reviewed at the next AHCCCS Pharmacy & Therapeutics Committee meeting
- Email requests sent to manufacturers to request supplemental rebate offers.
- The Offer Form- all manufactures must use a standardized form to submit supplemental rebate offers.
- All supplemental rebate offers are calculated using the same formula providing a guaranteed net unit price (GNUP) based on:

GNUP = Wholesale Acquisition Cost minus the Federal Rebate minus the Supplemental Rebate

- A Line extension form that will allow manufacturers to submit additions to their currently accepted rebate offer for new strengths or formulations of the initial drug offered during the contract year.
- Clinical Information for therapeutic classes or products that will be discussed at the next Pharmacy and Therapeutics Committee Meeting.
- Contact information for the Magellan Clinical Team managing Pharmacy & Therapeutics Review Process is located on the website

The drugs or drug classes to be covered at the next Pharmacy & Therapeutics Committee meeting on November 17, 2015 are:

- Self Injected Epinephrine
- Inhaled Corticosteroids - single agent and combination products
- Growth Hormone
- Cytokine and CAM (cell adhesion molecule) Antagonists